 |
市場調查報告書
商品編碼
1477229
1 型糖尿病市場，依設備類型、依胰島素類型、依最終用戶、依配銷通路、依地理位置Type 1 Diabetes Market, By Device Type, By Insulin Type, By End User, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
預計2024年全球1型糖尿病市場價值為159.5億美元，預計到2031年將達到243.6億美元，2024年至2031年年複合成長率(CAGR)為6.2%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2023年 | 2024 年市場規模： | 159.5 億美元 |
| 歷史數據： | 2019年至2023年 | 預測期： | 2024年至2031年 |
| 預測 2024 年至 2031 年複合年成長率： | 6.20% | 2031 年價值預測： | 243.6 億美元 |
圖 1. 1 型糖尿病市場佔有率 (%)（依地區），2024 年
1 型糖尿病是一種自體免疫疾病，胰臟產生很少或不產生胰島素。它是由於胰臟中產生胰島素的BETA細胞被破壞所造成的。胰島素是一種調節血糖的荷爾蒙。如果沒有胰島素，葡萄糖就會留在血液中，無法當作能量。結果，血糖（糖）水平變高。 1 型糖尿病的症狀包括口渴增加、排尿增加、食慾增加但體重減輕、視力模糊和疲倦。雖然第 1 型糖尿病無法治愈，但可以透過胰島素治療、飲食、運動和自我監測血糖水平來控制。全球 1 型糖尿病市場由用於監測和管理 1 型糖尿病患者血糖水平的設備和療法組成。
市場動態：
全球 1 型糖尿病市場的成長主要是由全球 1 型糖尿病盛行率上升所推動的。根據美國疾病管制與預防中心2023 年11 月發布的新聞稿，到2021 年，將有170 萬名年齡在20 歲或以上的成年人報告自己患有1 型糖尿病並使用胰島素，佔所有診斷為糖尿病的美國成年人的5.7%。人們對糖尿病管理和先進監測設備的認知不斷提高正在推動市場成長。然而，胰島素和其他管理療法的高成本對市場成長構成了重大課題。新技術帶來的連續血糖監測設備的改進為持續的市場擴張提供了有利可圖的機會。
研究的主要特點：
- 該報告對全球 1 型糖尿病市場進行了深入分析，並提供了以 2023 年為基準年的預測期（2024-2031 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
- 它闡明了不同區隔市場的潛在收入機會，並解釋了該市場有吸引力的投資主張矩陣。
- 這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
- 它根據以下參數描述了全球 1 型糖尿病市場的主要參與者——公司亮點、產品組合、主要亮點、財務表現和策略。
- 該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
- 全球 1 型糖尿病市場報告迎合了該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
- 利害關係人可以透過用於分析全球 1 型糖尿病市場的各種策略矩陣輕鬆做出決策。
目錄
第1章：研究目標與假設
- 研究目標
- 假設
- 縮寫
第 2 章：市場範圍
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map (COM)
第 3 章：市場動態、法規與趨勢分析
- 市場動態
- 促進要素
- 限制
- 市場機會
- 影響分析
- 市場走向
- 最近的發展
- 收購和合作場景
- 技術概覽
- 監管場景
- 定價分析
- PEST分析
第 4 章：全球 1 型糖尿病市場 - 冠狀病毒 (COVID-19) 大流行的影響
- 整體影響
- 政府舉措
- COVID-19 對市場的影響
第 5 章：2019 - 2031 年全球 1 型糖尿病市場（依設備類型）（十億美元）
- 概述
- 胰島素筆
- 胰島素注射器
- 胰島素幫浦
- 胰島素噴射注射器
第 6 章：全球第 1 型糖尿病市場，依胰島素類型，2019 - 2031 年（十億美元）
- 概述
- 長效胰島素
- 速效胰島素
第 7 章：全球 1 型糖尿病市場，依最終用戶分類，2019 - 2031 年（十億美元）
- 概述
- 家庭護理設置
- 醫院和診所
- 學術及研究機構
- 其他
第 8 章：全球 1 型糖尿病市場，依配銷通路，2019 年 - 2031 年，（十億美元）
- 概述
- 醫院藥房
- 零售藥局
- 網路藥局
第 9 章：2019 - 2031 年全球 1 型糖尿病市場（依地區）（十億美元）
- 介紹
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 歐洲其他地區
- 亞太地區
- 中國
- 印度
- 日本
- 東協
- 澳洲
- 韓國
- 亞太地區其他地區
- 中東
- 海灣合作理事會
- 以色列
- 中東其他地區
- 非洲
- 北非
- 中非
- 南非
第 10 章：競爭格局
- 公司簡介
- Biocon Ltd.
- Novo Nordisk
- Gan & Lee Pharmaceuticals
- Zealand Pharma
- AstraZeneca
- Eli Lilly and Company
- Sanofi
- Wockhardt Ltd.
- Ypsomed AG
- Novartis
- Panbela Therapeutics
- Diamyd Medical
- Adocia
- Anelixis Therapeutics
- Oramed Pharmaceuticals Inc.
第 11 章：分析師觀點
- 命運之輪
- 分析師觀點
- 連貫的機會圖
第 12 章：參考文獻與研究方法
- 參考
- 研究方法論
簡介目錄
Product Code: CMI6791
Global type 1 diabetes market is estimated to be valued at USD 15.95 Bn in 2024 and is expected to reach USD 24.36 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 15.95 Bn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 6.20% | 2031 Value Projection: | US$ 24.36 Bn |
Figure 1.Type 1 Diabetes Market Share (%), By Region, 2024
Type 1 diabetes is an autoimmune disease where the pancreas produces little or no insulin. It results from the destruction of insulin-producing beta cells in the pancreas. Insulin is a hormone that regulates blood sugar. Without insulin, glucose stays in the blood and cannot be used for energy. As a result, blood glucose (sugar) levels become high. Symptoms of type 1 diabetes include increased thirst, increased urination, weight loss despite increased appetite, blurred vision and tiredness. While there is no cure for type 1 diabetes, it can be managed through insulin therapy, diet, exercise, and self-monitoring of blood glucose levels. Global type 1 diabetes market consists of devices and therapeutics used for monitoring and managing blood glucose levels in type 1 diabetes patients.
Market Dynamics:
Global type 1 diabetes market growth is primarily driven by rising prevalence of type 1 diabetes across the world. According to Centers for Disease Control and Prevention press release published in November 2023, 1.7 million adults in 2021, aged 20 years or above which totals to 5.7% of all US adults with diagnosed diabetes reported that they have type 1 diabetes and use insulin. Increasing awareness regarding diabetes management and advanced monitoring devices are driving the market growth. However, high cost of insulin and other management therapies pose a major challenge to market growth. The improvements in continuous glucose monitoring devices enabled by new technologies provide lucrative opportunities for sustained market expansion.
Key Features of the Study:
- This report provides in-depth analysis of the global type 1 diabetes market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global type 1 diabetes market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study includes Biocon Ltd., Novo Nordisk, Gan & Lee Pharmaceuticals, Zealand Pharma, AstraZeneca, Eli Lilly and Company, Sanofi, Wockhardt Ltd., Ypsomed AG, Novartis, Panbela Therapeutics, Diamyd Medical, Adocia, Anelixis Therapeutics, and Oramed Pharmaceuticals Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global type 1 diabetes market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global type 1 diabetes market
Detailed Segmentation-
- By Device Type:
- Insulin Pen
- Insulin Syringe
- Insulin Pump
- Insulin Jet Injectors
- By Insulin Type:
- Long-Acting Insulin
- Rapid-Acting Insulin
- By End User:
- Homecare Settings
- Hospitals & Clinics
- Academic & Research Institutes
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Biocon Ltd.
- Novo Nordisk
- Gan & Lee Pharmaceuticals
- Zealand Pharma
- AstraZeneca
- Eli Lilly and Company
- Sanofi
- Wockhardt Ltd.
- Ypsomed AG
- Novartis
- Panbela Therapeutics
- Diamyd Medical
- Adocia
- Anelixis Therapeutics
- Oramed Pharmaceuticals Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Device Type
- Market Snapshot, By Insulin Type
- Market Snapshot, By End User
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
4. Global Type 1 Diabetes Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
5. Global Type 1 Diabetes Market, By Device Type, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Insulin Pen
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Insulin Syringe
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Insulin Pump
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Insulin Jet Injectors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
6. Global Type 1 Diabetes Market, By Insulin Type, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Long-Acting Insulin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Rapid-Acting Insulin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
7. Global Type 1 Diabetes Market, By End User, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Homecare Settings
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Hospitals & Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Academic & Research Institutes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
8. Global Type 1 Diabetes Market, By Distribution Channel, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
9. Global Type 1 Diabetes Market, By Region, 2019 - 2031, (USD BN)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2020-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Device Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Insulin Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Device Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Insulin Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Device Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Insulin Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Device Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Insulin Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Device Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Insulin Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Device Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Insulin Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Biocon Ltd.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novo Nordisk
- Gan & Lee Pharmaceuticals
- Zealand Pharma
- AstraZeneca
- Eli Lilly and Company
- Sanofi
- Wockhardt Ltd.
- Ypsomed AG
- Novartis
- Panbela Therapeutics
- Diamyd Medical
- Adocia
- Anelixis Therapeutics
- Oramed Pharmaceuticals Inc.
11. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
